Decentralized therapeutic platform trials for rare cancers have been embraced by a cooperative group (SWOG1609 [NCI] and the DART immunotherapy trial) as well as the NCI-MATCH genomics matching trial (both having been open at >1000 sites), a non-profit foundation (TargetCancer and the TRACK precision genomics trial), and a for-profit endeavor (Science37 Alpha-T ALK fusion targeting tissue-agnostic trial) (with the latter two using fully site-less care provided by a home oncologist). Here, ALK is linked to cancer.